QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
This retrospective study examined the effect of continuing active surveillance (AS) on the oncological outcomes in 531 patients on AS for prostate cancer (grade group 1; PSA level 20 mg/mL) who were subsequently upgraded to ≥GG2, and underwent further surveillance…
A nomogram has been developed to predict PSMA-PET scan results for recurrent prostate cancer. Medical nomograms use biologic and clinical variables, such as tumor grade and patient age to graphically depict a statistical predictive model that generates a probability of…
This retrospective analysis investigated whether the use of metformin and statins improve the overall survival and PSA response rate in men receiving abiraterone acetate plus prednisone/prednisolone (AAP) for metastatic castration-resistant prostate cancer (mCRPC) either before or after chemotherapy. The use…
Polygenic risk scores (PRS) of common genetic variants have shown promise in prostate cancer risk stratification, but their validity across different ethnic populations has yet to be confirmed. These researchers evaluated a multiethnic polygenic risk score model based on 269 germline genetic…
As post-prostatectomy urinary incontinence has a major impact on the quality of life of patients who had undergone radical prostatectomy, this study examined the effect of pelvic floor muscle exercise. Search in PubMed, Embase, and Cochrane Library databases resulted in…
Kristin Samuelson of Northwestern University, wrote an article entitled “Vitamins, supplements are a ‘waste of money’ for most Americans.” There is a lot of money spent by Americans on multivitamins and dietary supplements-close to $50 billion in 2021. This article…
Researchers at Johns Hopkins are finding that using high-dose testosterone makes cancer more receptive to other treatments. Androgen deprivation therapy (ADT) slows progression of prostate cancer by shutting off testosterone. Eventually cancer adapts to this environment and PSA levels start…
In men with PI-RADS 3 to 5 category lesions on their prostate MRI scans, Patel et al. demonstrate improved detection of clinically significant cancer (as well as a small decrease in detection of clinically insignificant disease) when targeted biopsies are…
The Italian American Chamber of Commerce Midwest is proud to present the 2022 Excellence Award to William Catalona, MD, Professor of Urology, Northwestern University, for his outstanding achievements and contributions. Previous award recipients include Riccardo Muti, Director, Chicago Symphony Orchestra,…
A targeted radioligand therapy, Pluvicto (lutetium LU 177 vipivotide tetraxetan), has been approved for use in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC). Eligible patients must have been treated previously with taxane-based chemotherapy and androgen deprivation therapy, and…
